A novel prosurvival model for cancer under environmental challenge: The "heart-felt" message for therapeutic intervention

Oncology Research

Volumn 19, Issue 8-9, 2011, Pages 407-443

  Loudon, John A ^a  

^a Stockland Mall   (Australia)

Author keywords

Cardiac pre postconditioning; Chemotherapy radiotherapy resistance; Dormant cancer; Hibernating myocardium; Ischemic myocardium; Prosurvival factors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; B RAF KINASE; BETA CATENIN; CANDESARTAN; CAPTOPRIL; CAVEOLIN; CISPLATIN; CLUSTERIN; ENALAPRIL; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45BETA; HEAT SHOCK PROTEIN 22; HEAT SHOCK PROTEIN 27; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYPOCALCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; REACTIVE OXYGEN METABOLITE; REPLICATION FACTOR C; SANGUINARINE; STAT PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ZINC FINGER PROTEIN;

ANGIOGENESIS; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL ACTIVATION; CELL METABOLISM; CELL SURVIVAL; COLON CANCER; DISEASE MODEL; DNA DAMAGE; DRUG TARGETING; GENE OVEREXPRESSION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PROTECTION; HIBERNATING MYOCARDIUM; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; PROSURVIVAL MODEL; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84255162104     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X13127606672832     Document Type: Review

References (269)

1. Vilain, D.; Bochet, J.; Le Stanc, E.; Wattel, C.; Hameg, A.; Tainturier, C. Unsuspected hibernating myocardium detected by routine oncology (18)F-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging 37:409; 2010.
2. Loudon, J. A.; Fukamizu, A.; Murakami, K.; Morris, B. J. Species differences in binding of submandibular nuclear proteins to renin promoter DNA. Clin. Exp. Pharmacol. Physiol. 20:283-288; 1993.
3. Petrovic, N.; Black, T. A.; Fabian, J. R.; Kane, C.; Jones, C. A.; Loudon, J. A.; Abonia, J. P.; Sigmund, C. D.; Gross, K. W. Role of proximal promoter elements in regulation of renin gene transcription. J. Biol. Chem. 271: 22499-22505; 1996.
4. Pan, L.; Black, T. A.; Shi, Q.; Jones, C. A.; Petrovic, N.; Loudon, J.; Kane, C.; Sigmund, C. D.; Gross, K. W. Critical roles of a cyclic AMP responsive element and an Ebox in regulation of mouse renin gene expression. J. Biol. Chem. 276:45530-45538; 2001.
5. Kinoshita, J.; Fushida, S.; Harada, S.; Yagi, Y.; Fujita, H.; Kinami, S.; Ninomiya, I.; Fujimura, T.; Kayahara, M.; Yashiro, M.; Hirakawa, K.; Ohta, T. Local angiotensin II-generation in human gastric cancer: Correlation with tumor progression through the activation of ERK1/ 2, NF-kappaB and survivin. Int. J. Oncol. 34:1573-1582; 2009.
6. Diaz, R. J.; Wilson, G. J. Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J. Mol. Cell. Cardiol. 29:129-139; 1997.
7. Shi, R. Z.; Wang, J. C.; Huang, S. H.; Wang, X. J.; Li, Q. P. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp. Cell Res. 315:10-15; 2009
8. Siddiqui, A. J.; Mansson-Broberg, A.; Gustafsson, T.; Grinnemo, K. H.; Dellgren, G.; Hao, X.; Fischer, H.; Sylvén, C. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am. J. Hypertens. 18:1347-1352; 2005.
9. Koh, S. L.; Ager, E. I.; Christophi, C. Liver regeneration and tumour stimulation: Implications of the renin-angiotensin system. Liver Int. 30:1414-1426; 2010.
10. Mascarenhas, A. K.; Allen, C. M.; Loudon, J. The association between Viadent use and oral leukoplakia. Epidemiology 12:741-743; 2001.
11. Allen, C. M.; Loudon, J.; Mascarenhas, A. K. Sanguinaria-related leukoplakia: Epidemiologic and clinico-pathologic features of a recently described entity. Gen. Dent. 49:608-614; 2001.
12. Anderson, K. M.; Stoner, G. D.; Fields, H. W.; Chacon, G. E.; Dohar, A. L.; Gregg, B. R.; Mallery, S. R. Immunohistochemical assessment of Viadent-associated leukoplakia. Oral Oncol. 41:200-207; 2005.
13. Choi, W. Y.; Kim, G. Y.; Lee, W. H.; Choi, Y. H. Sanguinarine, a benzophenanthridine alkaloid, induces apoptosis in MDA-MB-231 human breast carcinoma cells through a reactive oxygen species-mediated mitochondrial pathway. Chemotherapy 54:279-287; 2008.
14. De Stefano, I.; Raspaglio, G.; Zannoni, G. F.; Travaglia, D.; Prisco, M. G.; Mosca, M.; Ferlini, C.; Scambia, G.; Gallo, D. Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma. Biochem. Pharmacol. 78:1374-1381; 2009.
15. Karp, J. M.; Rodrigo, K. A.; Pei, P.; Pavlick, M. D.; Andersen, J. D.; McTigue, D. J.; Fields, H. W.; Mallery, S. R. Sanguinarine activates polycyclic aromatic hydrocarbon associated metabolic pathways in human oral keratinocytes and tissues. Toxicol. Lett. 158:50-60; 2005.
16. Depre, C.; Kim, S. J.; John, A. S.; Huang, Y.; Rimoldi, O. E.; Pepper, J. R.; Dreyfus, G. D.; Gaussin, V.; Pennell, D. J.; Vatner, D. E.; Camici, P. G.; Vatner, S. F. Program of cell survival underlying human and experimental hibernating myocardium. Circ. Res. 95:433-440; 2004.
17. May, D.; Gilon, D.; Djonov, V.; Itin, A.; Lazarus, A.; Gordon, O.; Rosenberger, C.; Keshet, E. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc. Natl. Acad. Sci. USA 105: 282-287; 2008.
18. Zohlnhöfer, D.; Nührenberg, T. G.; Haas, F.; Bengel, F.; Schömig, A.; Baeuerle, P. A.; Schwaiger, M. Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction. Heart Vessels 23:230-242; 2008.
19. Narayana, N.; Gist, J.; Smith, T.; Tylka, D.; Trogdon, G.; Wahl, J. K. Desmosomal component expression in normal, dysplastic, and oral squamous cell carcinoma. Dermatol. Res. Pract. 2010:649731; 2010.
20. Bauer, A.; Kleeff, J.; Bier, M.; Wirtz, M.; Kayed, H.; Esposito, I.; Korc, M.; Hafner, M.; Hoheisel, J. D.; Friess, H. Identification of malignancy factors by analyzing cystic tumors of the pancreas. Pancreatology 9:34-44; 2009.
21. Li, W.; Simarro, M.; Kedersha, N.; Anderson, P. FAST is a survival protein that senses mitochondrial stress and modulates TIA-1-regulated changes in protein expression. Mol. Cell. Biol. 24:10718-10732; 2004.
22. Berrada, N.; Delaloge, S.; André, F. Treatment of triple-negative metastatic breast cancer: Toward individualized targeted treatments or chemosensitization? Ann. Oncol. 21(Suppl. 7):vii30-vii35; 2010.
23. Hwang, I. G.; Ahn, M. J.; Park, B. B.; Ahn, Y. C.; Han, J.; Lee, S.; Kim, J.; Shim, Y. M.; Ahn, J. S.; Park, K. ERCC1 expression as a prognostic marker in N2(+) non- small-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379-1386; 2008.
24. Loudon, J. A. Cancer: A novel &"no-nonsense" approach to treatment. Oncol. Res. 19:55-66; 2010.
25. Indraccolo, S.; Stievano, L.; Minuzzo, S.; Tosello, V.; Esposito, G.; Piovan, E.; Zamarchi, R.; Chieco-Bianchi, L.; Amadori, A. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc. Natl. Acad. Sci. USA 103:4216-4221; 2006
26. Tanaka, T.; Cao, Y.; Folkman, J.; Fine, H. A. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58:3362-3369; 1998.
27. Suzuki, G.; Lee, T. C.; Fallavollita, J. A.; Canty, Jr., J. M. Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle. Circ. Res. 96: 767-775; 2005.
28. Macfarlane, L. A.; Murphy, P. R. Regulation of FGF-2 by an endogenous antisense RNA: Effects on cell adhesion and cell-cycle progression. Mol. Carcinog. 49: 1031-1044; 2010.
29. Erreni, M.; Solinas, G.; Brescia, P.; Osti, D.; Zunino, F.; Colombo, P.; Destro, A.; Roncalli, M.; Mantovani, A.; Draghi, R.; Levi, D.; Rodriguez, Y.; Baena, R.; Gaetani, P.; Pelicci, G.; Allavena, P. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur. J. Cancer 46:3383-3392; 2010.
30. Gao, S. Y.; Li, E. M.; Cui, L.; Lu, X. F.; Meng, L. Y.; Yuan, H. M.; Xie, J. J.; Du, Z. P.; Pang, J. X.; Xu, L. Y. Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J. Biol. Chem. 284: 7995-8004; 2009.
31. Melle, C.; Ernst, G.; Schimmel, B.; Bleul, A.; Mothes, H.; Kaufmann, R.; Settmacher, U.; Von Eggeling, F. Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int. J. Oncol. 28:195-200; 2006.
32. Takakura, S.; Kohno, T.; Manda, R.; Okamoto, A.; Tanaka, T.; Yokota, J. Genetic alterations and expression of the protein phosphatase 1 genes in human cancers. Int. J. Oncol. 18:817-824; 2001.
33. Qi, H.; Labrie, Y.; Grenier, J.; Fournier, A.; Fillion, C.; Labrie, C. Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells. Mol. Cell. Endocrinol. 182:181-192; 2001.
34. Scielzo, C.; Ghia, P.; Conti, A.; Bachi, A.; Guida, G.; Geuna, M.; Alessio, M.; Caligaris-Cappio, F. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J. Clin. Invest. 115:1644-1650; 2005.
35. Fischer, U.; Michel, A.; Meese, E. U. Expression of the gene for hematopoietic cell specific protein is not restricted to cells of hematopoietic origin. Int. J. Mol. Med. 15:611-615; 2005.
36. Zhu, X.; Li, C.; Sun, X.; Mao, Y.; Li, G.; Liu, X.; Zhang, Y.; Qiu, X. Immunoglobulin mRNA and protein expression in human oral epithelial tumor cells. Appl. Immunohistochem. Mol. Morphol. 16:232-238; 2008.
37. Vlecken, D. H.; Bagowski, C. P. LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer. Zebrafish 6:433-439; 2009.
38. Hsu, J. T.; Hsieh, Y. C.; Kan, W. H.; Chen, J. G.; Choudhry, M. A.; Schwacha, M. G.; Bland, K. I.; Chaudry, I. H. Role of p38 mitogen-activated protein kinase pathway in estrogen-mediated cardioprotection following trauma-hemorrhage. Am. J. Physiol. Heart Circ. Physiol. 292:2982-2987; 2007.
39. Leeksma, O. C.; Van Achterberg, T. A.; Tsumura, Y.; Toshima, J.; Eldering, E.; Kroes, W. G.; Mellink, C.; Spaargaren, M.; Mizuno, K.; Pannekoek, H.; de Vries, C. J. Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. Eur. J. Biochem. 269:2546-2556; 2002.
40. Nielsen, A. A.; Kjartansdóttir, K. R.; Rasmussen, M. H.; Sørensen, A. B.; Wang, B.; Wabl, M.; Pedersen, F. S. Activation of the brain-specific neurogranin gene in murine T-cell lymphomas by proviral insertional mutagenesis. Gene 442:55-62; 2009.
41. Mauchley, D.; Meng, X.; Johnson, T.; Fullerton, D. A.; Weyant, M. J. Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2). J. Thorac. Cardiovasc. Surg. 139:591-599; 2010.
42. Watabe, Y.; Nazuka, N.; Tezuka, M.; Shimba, S. Aryl hydrocarbon receptor functions as a potent coactivator of E2F1-dependent trascription activity. Biol. Pharm. Bull. 33:389-397; 2010.
43. Ali, N. A.; McKay, M. J.; Molloy, M. P. Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells. Mol. Biosyst. 6:2332-2338; 2010.
44. Su, Y.; Loos, M.; Giese, N.; Hines, O. J.; Diebold, I.; Görlach, A.; Metzen, E.; Pastorekova, S.; Friess, H.; Büchler, P. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br. J. Cancer 103: 1571-1579; 2010.
45. O'Malley, S.; Su, H.; Zhang, T.; Ng, C.; Ge, H.; Tang, C. K. TOB suppresses breast cancer tumorigenesis. Int. J. Cancer 125:1805-1813; 2009.
46. Swanson-Mungerson, M.; Bultema, R.; Longnecker, R. Epstein-Barr virus LMP2A imposes sensitivity to apoptosis. J. Gen. Virol. 91:2197-2202; 2010.
47. Sun, J.; Xu, X.; Liu, J.; Liu, H.; Fu, L.; Gu, L. Epigenetic regulation of retinoic acid receptor beta2 gene in the initiation of breast cancer. Med. Oncol., in press; 2011.
48. Kotake, Y.; Zeng, Y.; Xiong, Y. DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation. Cancer Res. 69(5):1809-1814; 2009.
49. Bralten, L. B.; Kloosterhof, N. K.; Gravendeel, L. A.; Sacchetti, A.; Duijm, E. J.; Kros, J. M.; van den Bent, M. J.; Hoogenraad, C. C.; Sillevis Smitt, P. A.; French, P. J. Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. Genes Chromosomes Cancer 49: 509-517; 2010.
50. Canatan, H. The effect of cardiac ischemic preconditioning on rat left ventricular gene expression profile. Cell Biochem. Funct. 26:179-184; 2008.
51. Deli, T.; Varga, N.; Adám, A.; Kenessey, I.; Rásó, E.; Puskás, L. G.; Tóvári, J.; Fodor, J.; Fehér, M.; Szigeti, G. P.; Csernoch, L.; Tímár, J. Functional genomics of calcium channels in human melanoma cells. Int. J. Cancer 121:55-65; 2007.
52. Addya, S.; Shiroto, K.; Turoczi, T.; Zhan, L.; Kaga, S.; Fukuda, S.; Surrey, S.; Duan, L. J.; Fong, G. H.; Yamamoto, F.; Maulik, N. Ischemic preconditioning-mediated cardioprotection is disrupted in heterozygous Flt-1 (VEGFR-1) knockout mice. J. Mol. Cell Cardiol. 38: 345-351; 2005.
53. Yan, W.; Chen, X. Identification of GRO1 as a critical determinant for mutant p53 gain of function. J. Biol. Chem. 284:12178-12187; 2009.
54. Sun, M. Z.; Liu, S.; Tang, J.; Wang, Z.; Gong, X.; Sun, C.; Greenaway, F. Proteomics analysis of two mice hepatocarcinoma ascites syngeneic cell lines with high and low lymph node metastasis rates provide potential protein markers for tumor malignancy attributes to lymphatic metastasis. Proteomics 9:3285-3302; 2009.
55. Bender, A. M.; Collier, L. S.; Rodriguez, F. J.; Tieu, C.; Larson, J. D.; Halder, C.; Mahlum, E.; Kollmeyer, T. M.; Akagi, K.; Sarkar, G.; Largaespada, D. A.; Jenkins, R. B. Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. Cancer Res. 70:3557-3565; 2010.
56. Yang, J.; Splittgerber, R.; Yull, F. E.; Kantrow, S.; Ayers, G. D.; Karin, M.; Richmond, A. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J. Clin. Invest. 120:2563-2574; 2010.
57. da Silva, R.; Lucchinetti, E.; Pasch, T.; Schaub, M. C.; Zaugg, M. Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium. Physiol. Genomics 20:117-130; 2004.
58. Kuo, P. L.; Chen, Y. H.; Chen, T. C.; Shen, K. H.; Hsu, Y. L. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/Snail signaling pathway. J. Cell Physiol. 226:1224-1231; 2011.
59. Yin, X.; Wolford, C. C.; Chang, Y. S.; McConoughey, S. J.; Ramsey, S. A.; Aderem, A.; Hai, T. ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J. Cell Sci. 123:3558-3565; 2010.
60. Izumi, H.; Wakasugi, T.; Shimajiri, S.; Tanimoto, A.; Sasaguri, Y.; Kashiwagi, E.; Yasuniwa, Y.; Akiyama, M.; Han, B.; Wu, Y.; Uchiumi, T.; Arao, T.; Nishio, K.; Yamazaki, R.; Kohno, K. Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell-cycle-associated genes. Cancer Sci. 101: 2538-2545; 2010.
61. Torigoe, T.; Izumi, H.; Ishiguchi, H.; Yoshida, Y.; Tanabe, M.; Yoshida, T.; Igarashi, T.; Niina, I.; Wakasugi, T.; Imaizumi, T.; Momii, Y.; Kuwano, M.; Kohno, K. Cisplatin resistance and transcription factors. Curr. Med. Chem. Anticancer Agents 5:15-27; 2005.
62. Li, J.; Wang, Y.; Fan, X.; Mo, X.; Wang, Z.; Li, Y.; Yin, Z.; Deng, Y.; Luo, N.; Zhu, C.; Liu, M.; Ma, Q.; Ocorr, K.; Yuan, W.; Wu, X. ZNF307, a novel zinc finger gene suppresses p53 and p21 pathway. Biochem. Biophys. Res. Commun. 363:895-900; 2007.
63. Tsao, C. C.; Corn, P. MDM-2 antagonists induce p53- dependent cell cycle arrest but not cell death in renal cancer cell lines. Cancer Biol Ther. 10:1315-1325; 2011.
64. Secchiero, P.; di Iasio, M. G.; Gonelli, A.; Zauli, G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr. Pharm. Des. 14:2100-2110; 2008.
65. Qu, S.; Zhu, H.; Wei, X.; Zhang, C.; Jiang, L.; Liu, Y.; Luo, Q.; Xiao, X. Oxidative stress-mediated up-regulation of myocardial ischemic preconditioning up-regulated protein 1 gene expression in H9c2 cardiomyocytes is regulated by cyclic AMP-response element binding protein. Free Radic. Biol. Med. 49:580-586; 2010.
66. Arrell, D. K.; Elliott, S. T.; Kane, L. A.; Guo, Y.; Ko, Y. H.; Pedersen, P. L.; Robinson, J.; Murata, M.; Murphy, A. M.; Marbán, E.; Van Eyk, J. E. Proteomic analysis of pharmacological preconditioning: Novel protein targets converge to mitochondrial metabolism pathways. Circ. Res. 99:706-714; 2006.
67. Ala-Rämi, A.; Ylitalo, K. V.; Hassinen, I. E. Ischaemic preconditioning and a mitochondrial KATP channel opener both produce cardioprotection accompanied by F1F0-ATPase inhibition in early ischaemia. Basic Res. Cardiol. 98:250-258; 2003.
68. Willers, I. M.; Isidoro, A.; Ortega, A. D.; Fernández, P. L.; Cuezva, J. M. Selective inhibition of beta-F1- ATPase mRNA translation in human tumours. Biochem. J. 426:319-326; 2010.
69. Willers, I. M.; Cuezva, J. M. Post-transcriptional regulation of the mitochondrial H(+)-ATP synthase: A key regulator of the metabolic phenotype in cancer. Biochim. Biophys. Acta 1807(6):543-551; 2011.
70. Roche, T. E.; Hiromasa, Y.; Turkan, A.; Gong, X.; Peng, T.; Yan, X.; Kasten, S. A.; Bao, H.; Dong, J. Essential roles of lipoyl domains in the activated function and control of pyruvate dehydrogenase kinases and phosphatase isoform 1. Eur. J. Biochem. 270:1050-1056; 2003.
71. Clarke, S. J.; Khaliulin, I.; Das, M.; Parker, J. E.; Heesom, K. J.; Halestrap, A. P. Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation. Circ. Res. 102:1082-1090; 2008.
72. Ling, X.; Zhou, Y.; Li, S. W.; Yan, B.; Wen, L. Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells. Int. J. Biol. Sci. 6:773-783; 2010.
73. Duan, X.; Young, R.; Straubinger, R. M.; Page, B.; Cao, J.; Wang, H.; Yu, H.; Canty, J. M.; Qu, J. A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J. Proteome Res. 8:2838-2850; 2009.
74. Yu, J. S.; Koujak, S.; Nagase, S.; Li, C. M.; Su, T.; Wang, X.; Keniry, M.; Memeo, L.; Rojtman, A.; Mansukhani, M.; Hibshoosh, H.; Tycko, B.; Parsons, R. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27:4657-4665; 2008.
75. Seiler, N. Catabolism of polyamines. Amino Acids 26: 217-233; 2004.
76. Yamashita, H.; Noguchi, S.; Murakami, N.; Yokoyama, S.; Nakayama, I. Loss of intracellular peroxidase and anaplastic change of differentiated carcinoma of human thyroid gland. Acta Pathol. Jpn. 37:425-430; 1987.
77. Artero-Castro, A.; Castellvi, J.; García, A.; Hernández, J.; Cajal, S. R.; Lleonart, M. E. Expression of the ribosomal proteins Rplp0, Rplp1, and Rplp2 in gynecologic tumors. Hum. Pathol. 42:194-203; 2011.
78. Page, B.; Young, R.; Iyer, V.; Suzuki, G.; Lis, M.; Korotchkina, L.; Patel, M. S.; Blumenthal, K. M.; Fallavollita, J. A.; Canty, Jr., J. M. Persistent regional downregulation in mitochondrial enzymes and upregulation of stress proteins in swine with chronic hibernating myocardium. Circ. Res. 102:103-112; 2008.
79. Launay, N.; Tarze, A.; Vicart, P.; Lilienbaum, A. Serine 59 phosphorylation of áB-crystallin down-regulates its anti-apoptotic function by binding and sequestering Bcl- 2 in breast cancer cells. J. Biol. Chem. 285:37324-3732; 2010
80. Kuo, T. C.; Chiang, P. C.; Yu, C. C.; Bastow, K. F.; Lee, K. H.; Guh, J. H. A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways. Biochem. Pharmacol. 81(9):1136-1144; 2011.
81. Ma, Y.; Peng, J.; Liu, W.; Zhang, P.; Huang, L.; Gao, B.; Shen, T.; Zhou, Y.; Chen, H.; Chu, Z.; Zhang, M.; Qin, H. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics 8:1878-1890; 2009
82. Hsu, W. M.; Lee, H.; Juan, H. F.; Shih, Y. Y.; Wang, B. J.; Pan, C. Y.; Jeng, Y. M.; Chang, H. H.; Lu, M. Y.; Lin, K. H.; Lai, H. S.; Chen, W. J.; Tsay, Y. G.; Liao, Y. F.; Hsieh, F. J. Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis. Clin. Cancer Res. 14:6237-6245; 2008.
83. Chacko, A. D.; Liberante, F.; Paul, I.; Longley, D. B.; Fennell, D. A. Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8. BMC Cancer 10:380-388; 2010.
84. Grills, C.; Jithesh, P. V.; Blayney, J.; Zhang, S. D.; Fennell, D. A. Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS One 6:e14635, 1-8; 2011.
85. Tsui, K. H.; Feng, T. H.; Lin, Y. F.; Chang, P. L.; Juang, H. H. p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. Prostate 71:62-70; 2011.
86. Wang, D.; DuBois, R. N. Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol. Clin. North Am. 39:697-707; 2010.
87. Levine, A. J.; Puzio-Kuter, A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340-1344; 2010.
88. Younce, C. W.; Kolattukudy, P. E. MCP-1 causes cardiomyoblast death via autophagy resulting from ER stress caused by oxidative stress generated by inducing a novel zinc-finger protein, MCPIP. Biochem. J. 426:43-53; 2010.
89. Skalniak, L.; Mizgalska, D.; Zarebski, A.; Wyrzykowska, P.; Koj, A.; Jura, J. Regulatory feedback loop between NF-kappaB and MCP-1-induced protein 1 RNase. FEBS J. 276:5892-5905; 2009.
90. Venkatesan, B.; Prabhu, S. D.; Venkatachalam, K.; Mummidi, S.; Valente, A. J.; Clark, R. A.; Delafontaine, P.; Chandrasekar, B. WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal 22:809-820; 2010.
91. Davies, S. R.; Davies, M. L.; Sanders, A.; Parr, C.; Torkington, J.; Jiang, W. G. Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications. Int. J. Oncol. 36:1129-1136; 2010.
92. Lee, Y. S.; Oh, J. H.; Yoon, S.; Kwon, M. S.; Song, C. W.; Kim, K. H.; Cho, M. J.; Mollah, M. L.; Je, Y. J.; Kim, Y. D.; Kim, C. D.; Lee, J. H. Differential gene expression profiles of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: Tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 77:858-866; 2010.
93. McFalls, E. O.; Hou, M.; Bache, R. J.; Best, A.; Marx, D.; Sikora, J.; Ward, H. B. Activation of p38 MAPK and increased glucose transport in chronic hibernating swine myocardium. Am. J. Physiol. Heart Circ. Physiol. 287: 1328-1334; 2004.
94. Liu, D.; He, M.; Yi, B.; Guo, W. H.; Que, A. L.; Zhang, J. X. Pim-3 protects against cardiomyocyte apoptosis in anoxia/reoxygenation injury via p38-mediated signal pathway. Int. J. Biochem. Cell Biol. 41:2315-2322; 2009.
95. Adam, A. P.; George, A.; Schewe, D.; Bragado, P.; Iglesias, B. V.; Ranganathan, A. C.; Kourtidis, A.; Conklin, D. S.; Aguirre-Ghiso, J. A. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res. 69:5664-5672; 2009.
96. Matrone, A.; Grossi, V.; Chiacchiera, F.; Fina, E.; Cappellari, M.; Caringella, A. M.; Di Naro, E.; Loverro, G.; Simone, C. p38alpha is required for ovarian cancer cell metabolism and survival. Int. J. Gynecol. Cancer 20: 203-211; 2010.
97. Ranganathan, A. C.; Adam, A. P.; Zhang, L.; Aguirre- Ghiso, J. A. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol. Ther. 5:729-735; 2006.
98. Ranganathan, A. C.; Adam, A. P.; Aguirre-Ghiso, J. A. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 5: 1799-1807; 2006.
99. Essers, M. A.; Trumpp, A. Targeting leukemic stem cells by breaking their dormancy. Mol. Oncol. 4:443-450; 2010.
100. Ossowski, L.; Aguirre-Ghiso, J. A. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. 23:41-56; 2010.
101. Li, B.; Smith, C. C.; Laing, J. M.; Gober, M. D.; Liu, L.; Aurelian, L. Overload of the heat-shock protein H11/ HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1. Oncogene 26:3521-3531; 2007.
102. Hausenloy, D. J.; Mocanu, M. M.; Yellon, D. M. Cross- talk between the survival kinases during early reperfusion: Its contribution to ischemic preconditioning. Cardiovasc. Res. 63:305-312; 2004.
103. Doroudgar, S.; Thuerauf, D. J.; Marcinko, M. C.; Belmont, P. J.; Glembotski, C. C. Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response. J. Biol. Chem. 284:29735-29745; 2009.
104. Schewe, D. M.; Aguirre-Ghiso, J. A. ATF6alpha-Rheb- mTOR signaling promotes survival of dormant tumor cells in vivo. Proc. Natl. Acad. Sci. USA 105:10519-10524; 2008.
105. Lu, X.; Liu, H.; Wang, L.; Schaefer, S. Activation of NF- kappaB is a critical element in the antiapoptotic effect of anesthetic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 296:1296-1304; 2009.
106. Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. Modelling Myc inhibition as a cancer therapy. Nature 455:679-683; 2008.
107. Ahuja, P.; Zhao, P.; Angelis, E.; Ruan, H.; Korge, P.; Olson, A.; Wang, Y.; Jin, E. S.; Jeffrey, F. M.; Portman, M.; Maclellan, W. R. Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J. Clin. Invest. 120:1494-1505; 2010.
108. Dang, C. V.; Le, A.; Gao, P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15:6479-6483; 2009.
109. Law, A. Y.; Wong, C. K. Stanniocalcin-2 promotes epithelial- mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp. Cell Res. 316: 3425-3434; 2010.
110. Westberg, J. A.; Serlachius, M.; Lankila, P.; Andersson, L. C. Hypoxic preconditioning induces elevated expression of stanniocalcin-1 in the heart. Am. J. Physiol. Heart Circ. Physiol. 293:1766-1771; 2007.
111. Liu, G.; Yang, G.; Chang, B.; Mercado-Uribe, I.; Huang, M.; Zheng, J.; Bast, R. C.; Lin, S. H.; Liu, J. Stanniocalcin 1 and ovarian tumorigenesis. J. Natl. Cancer Inst. 102:812-827; 2010.
112. Yokobori, T.; Mimori, K.; Ishii, H.; Iwatsuki, M.; Tanaka, F.; Kamohara, Y.; Ieta, K.; Kita, Y.; Doki, Y.; Kuwano, H.; Mori, M. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann. Surg. Oncol. 17:2601-2607; 2010.
113. Yan, G. R.; Ding, W.; Xu, S. H.; Xu, Z.; Xiao, C. L.; Yin, X. F.; He, Q. Y. Characterization of phosphoproteins in gastric cancer secretome. OMICS 15:83-90; 2011.
114. Fujiwara, Y.; Sugita, Y.; Nakamori, S.; Miyamoto, A.; Shiozaki, K.; Nagano, H.; Sakon, M.; Monden, M. Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int. J. Oncol. 16:799-804; 2000.
115. Wascher, R. A.; Huynh, K. T.; Giuliano, A. E.; Hansen, N. M.; Singer, F. R.; Elashoff, D.; Hoon, D. S. Stannio-calcin-1: A novel molecular blood and bone marrow marker for human breast cancer. Clin. Cancer Res. 9: 1427-1435; 2003.
116. Tohmiya, Y.; Koide, Y.; Fujimaki, S.; Harigae, H.; Funato, T.; Kaku, M.; Ishii, T.; Munakata, Y.; Kameoka, J.; Sasaki, T. Stanniocalcin-1 as a novel marker to detect minimal residual disease of human leukemia. Tohoku J. Exp. Med. 204:125-133; 2004.
117. Chirgwin, J. M.; Mohammad, K. S.; Guise, T. A. Tumor- bone cellular interactions in skeletal metastases. J. Musculoskelet. Neuronal Interact. 4:308-318; 2004.
118. Korah, R.; Boots, M.; Wieder, R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: An in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res. 64:4514-4522; 2004.
119. Miyamoto, S.; Purcell, N. H.; Smith, J. M.; Gao, T.; Whittaker, R.; Huang, K.; Castillo, R.; Glembotski, C. C.; Sussman, M. A.; Newton, A. C.; Brown, J. H. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ. Res. 107:476-484; 2010.
120. Danan, I. J.; Rashed, E. R.; Depre, C. Therapeutic potential of H11 kinase for the ischemic heart. Cardiovasc. Drug Rev. 25:14-29; 2007.
121. Wadhwa, R.; Ryu, J.; Gao, R.; Choi, I. K.; Morrow, G.; Kaur, K.; Kim, I.; Kaul, S. C.; Yun, C. O.; Tanguay, R. M. Proproliferative functions of Drosophila small mitochondrial heat shock protein 22 in human cells. J. Biol. Chem. 285:3833-3839; 2010.
122. Sun, X.; Fontaine, J. M.; Bartl, I.; Behnam, B.; Welsh, M. J.; Benndorf, R. Induction of Hsp22 (HspB8) by estrogen and the metalloestrogen cadmium in estrogen receptor-positive breast cancer cells. Cell Stress Chaperones 12:307-319; 2007.
123. Yang, C.; Trent, S.; Ionescu-Tiba, V.; Lan, L.; Shioda, T.; Sgroi, D.; Schmidt, E. V. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res. 66:11649-11658; 2006.
124. Yu, Y. X.; Heller, A.; Liehr, T.; Smith, C. C.; Aurelian, L. Expression analysis and chromosome location of a novel gene (H11) associated with the growth of human melanoma cells. Int. J. Oncol. 18:905-911; 2001.
125. Lochner, A.; Marais, E.; Genade, S.; Huisamen, B.; du Toit, E. F.; Moolman, J. A. Protection of the ischaemic heart: Investigations into the phenomenon of ischaemic preconditioning. Cardiovasc. J. Afr. 20:43-51; 2009.
126. Chandrika, B. B.; Maney, S. K.; Lekshmi, S. U.; Retnabhai, S. T. Endoplasmic reticulum targeted Bcl2 confers long term cell survival through phosphorylation of heat shock protein 27. Int. J. Biochem. Cell Biol. 42:1984-1992; 2010.
127. Rylander, M. N.; Feng, Y.; Zimmermann, K.; Diller, K. R. Measurement and mathematical modeling of thermally induced injury and heat shock protein expression kinetics in normal and cancerous prostate cells. Int. J. Hyperthermia 26:748-764; 2010.
128. Wagner, M.; Siddiqui, M. A. Signaling networks regulating cardiac myocyte survival and death. Curr. Opin. Investig. Drugs 10:928-937; 2009.
129. Boengler, K.; Hilfiker-Kleiner, D.; Drexler, H.; Heusch, G.; Schulz, R. The myocardial JAK/STAT pathway: From protection to failure. Pharmacol. Ther. 120:172-185; 2008.
130. Wagner, M.; Siddiqui, M. A. Signaling networks regulating cardiac myocyte survival and death. Curr. Opin. Investig. Drugs 10:928-937; 2009.
131. Shi, M.; Liu, D.; Duan, H.; Han, C.; Wei, B.; Qian, L.; Chen, C.; Guo, L.; Hu, M.; Yu, M.; Song, L.; Shen, B.; Guo, N. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Mol. Cancer 9:269; 2010.
132. Yoon, S.; Woo, S. U.; Kang, J. H.; Kim, K.; Kwon, M. H.; Park, S.; Shin, H. J.; Gwak, H. S.; Chwae, Y. J. STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells. Autophagy 6:1125-1138; 2010.
133. Zhong, B.; Sallman, D. A.; Gilvary, D. L.; Pernazza, D.; Sahakian, E.; Fritz, D.; Cheng, J. Q.; Trougakos, I.; Wei, S.; Djeu, J. Y. Induction of clusterin by AKT - role in cytoprotection against docetaxel in prostate tumor cells. Mol. Cancer Ther. 9:1831-1841; 2010.
134. Patterson, S. G.; Wei, S.; Chen, X.; Sallman, D. A.; Gilvary, D. L.; Zhong, B.; Pow-Sang, J.; Yeatman, T.; Djeu, J. Y. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25:6113-6122; 2006.
135. Krijnen, P. A.; Niessen, H. W. The antiapoptotic protein clusterin protects cardiomyocytes against ischemia-induced cell death. Am. J. Physiol. Heart Circ. Physiol. 293:3223; 2007.
136. You, L.; Li, L.; Xu, Q.; Ren, J.; Zhang, F. Postconditioning reduces infarct size and cardiac myocyte apoptosis via the opioid receptor and JAK-STAT signaling pathway. Mol. Biol. Rep. 38:437-443; 2011.
137. Luanpitpong, S.; Talbott, S. J.; Rojanasakul, Y.; Nimmannit, U.; Pongrakhananon, V.; Wang, L.; Chanvorachote, P. Regulation of lung cancer cell migration and invasion by reactive oxygen species and Caveolin-1. J. Biol. Chem. 285:38832-38840; 2010.
138. Park, J.; Bae, E.; Lee, C.; Yoon, S. S.; Chae, Y. S.; Ahn, K. S.; Won, N. H. RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol. 31:643-650; 2010.
139. Patel, H. H.; Tsutsumi, Y. M.; Head, B. P.; Niesman, I. R.; Jennings, M.; Horikawa, Y.; Huang, D.; Moreno, A. L.; Patel, P. M.; Insel, P. A.; Roth, D. M. Mechanisms of cardiac protection from ischemia/reperfusion injury: A role for caveolae and caveolin-1. FASEB J. 21:1565-1574; 2007.
140. Kim, M. Y.; Seo, E. J.; Lee, D. H.; Kim, E. J.; Kim, H. S.; Cho, H. Y.; Chung, E. Y.; Lee, S. H.; Baik, E. J.; Moon, C. H.; Jung, Y. S. Gadd45beta is a novel mediator of cardiomyocyte apoptosis induced by ischaemia/hypoxia. Cardiovasc. Res. 87:119-126; 2010.
141. Qiu, W.; Zhou, B.; Chu, P. G.; Luh, F.; Yen, Y. The induction of growth arrest DNA damage-inducible gene 45 beta in human hepatoma cell lines by S-adenosyl- methionine. Am. J. Pathol. 171:287-296; 2007.
142. Zhang, Q.; Zhao, X. H.; Wang, Z. J. Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem. Toxicol. 46:2042-2053; 2008.
143. Cohen, M. V.; Philipp, S.; Krieg, T.; Cui, L.; Kuno, A.; Solodushko, V.; Downey, J. M. Preconditioning-mimetics bradykinin and DADLE activate PI3-kinase through divergent pathways. J. Mol. Cell. Cardiol. 42:842-851; 2007.
144. Krieg, T.; Cui, L.; Qin, Q.; Cohen, M. V.; Downey, J. M. Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metallo- proteinase cleavage of proHB-EGF. J. Mol. Cell. Cardiol. 36:435-443; 2004.
145. Kim, J.; Adam, R. M.; Freeman, M. R. Trafficking of nuclear heparin-binding epidermal growth factor-like growth factor into an epidermal growth factor receptor-dependent autocrine loop in response to oxidative stress. Cancer Res. 65:8242-8249; 2005.
146. de la Roche, M.; Worm, J.; Bienz, M. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells. BMC Cancer 8:199-212; 2008.
147. Chikazawa, N.; Tanaka, H.; Tasaka, T.; Nakamura, M.; Tanaka, M.; Onishi, H.; Katano, M. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 30: 2041-2048; 2010.
148. Kaga, S.; Zhan, L.; Altaf, E.; Maulik, N. Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J. Mol. Cell. Cardiol. 40:138-147; 2006.
149. Naito, A. T.; Okada, S.; Minamino, T.; Iwanaga, K.; Liu, M. L.; Sumida, T.; Nomura, S.; Sahara, N.; Mizoroki, T.; Takashima, A.; Akazawa, H.; Nagai, T.; Shiojima, I.; Komuro, I. Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury. Circ Res. 106:1692-1702; 2010.
150. Song, H. P.; Zhang, L.; Dang, Y. M.; Yan, H.; Chu, Z. G.; Huang, Y. S. The phosphatidylinositol 3-kinase- Akt pathway protects cardiomyocytes from ischaemic and hypoxic apoptosis via mitochondrial function. Clin. Exp. Pharmacol. Physiol. 37:598-604; 2010.
151. Zhang, L. J.; Huang, H.; Pan, P. X.; Liu, X. J.; Wu, W. C.; Fu, H. Study on the expression of activin-A in myocardial ischemia postconditioning. Sichuan Da Xue Xue Bao Yi Xue Ban. 40:97-99; 2009.
152. Keyes, K. T.; Xu, J.; Long, B.; Zhang, C.; Hu, Z.; Ye, Y. Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postin- farction. Am. J. Physiol. Heart Circ. Physiol. 298:1198-1208; 2010.
153. Cheng, Y.; Zhang, C. MicroRNA-21 in cardiovascular disease. J. Cardiovasc. Transl. Res. 3:251-255; 2010.
154. Sayed, D.; He, M.; Hong, C.; Gao, S.; Rane, S.; Yang, Z.; Abdellatif, M. MicroRNA-21 is a downstream ef- fector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J. Biol. Chem. 285:20281-20290; 2010.
155. Cheng, Y.; Liu, X.; Zhang, S.; Lin, Y.; Yang, J.; Zhang, C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J. Mol. Cell. Cardiol. 47:5-14; 2009.
156. Bonci, D. MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. Recent Pat. Cardiovasc. Drug Discov. 5:156-161; 2010.
157. Lu, H. H.; Kao, S. Y.; Liu, T. Y.; Liu, S. T.; Huang, W. P.; Chang, K. W.; Lin, S. C. Areca nut extract in- duced oxidative stress and upregulated hypoxia inducing factor leading to autophagy in oral cancer cells. Autoph- agy 6:725-737; 2010.
158. Yan, L.; Sadoshima, J.; Vatner, D. E.; Vatner, S. F. Au- tophagy in ischemic preconditioning and hibernating myocardium. Autophagy 5:709-712; 2009.
159. Matsui, Y.; Takagi, H.; Qu, X.; Abdellatif, M.; Sakoda, H.; Asano, T.; Levine, B.; Sadoshima, J. Distinct roles of autophagy in the heart during ischemia and reperfu- sion: Roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ. Res. 100:914-922; 2007.
160. Li, Z.; Chen, B.; Wu, Y.; Jin, F.; Xia, Y.; Liu, X. Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer 10:98-110; 2010.
161. Bhui, K.; Tyagi, S.; Prakash, B.; Shukla, Y. Pineapple bromelain induces autophagy, facilitating apoptotic response in mammary carcinoma cells. Biofactors 36:474-482; 2010.
162. Yang, P. M.; Liu, Y. L.; Lin, Y. C.; Shun, C. T.; Wu, M. S.; Chen, C. C. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 70:7699-7709; 2010.
163. Young, L. H. AMP-activated protein kinase conducts the ischemic stress response orchestra. Circulation 117:832-840; 2008.
164. Karna, P.; Zughaier, S.; Pannu, V.; Simmons, R.; Narayan, S.; Aneja, R. Induction of reactive oxygen species-mediated autophagy by a novel microtubule-modulating agent. J. Biol. Chem. 285:18737-18748; 2010.
165. Filomeni, G.; Desideri, E.; Cardaci, S.; Graziani, I.; Piccirillo, S.; Rotilio, G.; Ciriolo, M. R. Carcinoma cells activate AMP-activated protein kinase-dependent autophagy as survival response to kaempferol-mediated energetic impairment. Autophagy 6:202-216; 2010.
166. Mazure, N. M.; Pouysségur, J. Hypoxia-induced autophagy: Cell death or cell survival? Curr. Opin. Cell Biol. 22:177-180; 2010.
167. Shaw, R. J. Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18:598-608; 2006.
168. Cadenas, S.; Aragonés, J.; Landázuri, M. O. Mitochondrial reprogramming through cardiac oxygen sensors in ischaemic heart disease. Cardiovasc. Res. 88:219-228; 2010.
169. Smith, T. G.; Talbot, N. P. Prolyl hydroxylases and therapeutics. Antioxid Redox Signal 12:431-433; 2010.
170. Natsuizaka, M.; Ozasa, M.; Darmanin, S.; Miyamoto, M.; Kondo, S.; Kamada, S.; Shindoh, M.; Higashino, F.; Suhara, W.; Koide, H.; Aita, K.; Nakagawa, K.; Kondo, T.; Asaka, M.; Okada, F.; Kobayashi, M. Synergistic up-regulation of hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp. Cell Res. 313:3337-3348; 2007.
171. Spangenberg, C.; Lausch, E. U.; Trost, T. M.; Prawitt, D.; May, A.; Keppler, R.; Fees, S. A.; Reutzel, D.; Bell, C.; Schmitt, S.; Schiffer, I. B.; Weber, A.; Brenner, W.; Hermes, M.; Sahin, U.; Türeci, O.; Koelbl, H.; Hengstler, J. G.; Zabel, B. U. ERBB2-mediated transcriptional upregulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res. 66:3715-3725; 2006.
172. Yewalkar, N.; Deore, V.; Padgaonkar, A.; Manohar, S.; Sahu, B.; Kumar, P.; Jalota-Badhwar, A.; Joshi, K. S.; Sharma, S.; Kumar, S. Development of novel inhibitors targeting HIF-1alpha towards anticancer drug discovery. Bioorg. Med. Chem. Lett. 20:6426-6429; 2010.
173. Lee, M.; Hwang, J. T.; Yun, H.; Kim, E.; Kim, M. J.; Kim, S. S.; Ha, J. Critical roles of AMP-activated protein kinase in the carcinogenic metal-induced expression of VEGF and HIF-1 proteins in DU145 prostate carcinoma. Biochem. Pharmacol. 72:91-103; 2006.
174. Lee, M.; Hwang, J. T.; Lee, H.; Jung, S. N.; Kan, I.; Chi, S. G.; Kim, S. S.; Ha, J. AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J. Biol. Chem. 278: 39653-39661; 2003.
175. Neurath, K. M.; Keough, M. P.; Mikkelsen, T.; Claffey, K. P. AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma. Glia 53:733-43; 2006.
176. Shimano, M.; Ouchi, N.; Shibata, R.; Ohashi, K.; Pimentel, D. R.; Murohara, T.; Walsh, K. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J. Mol. Cell. Cardiol. 49:210-220; 2010.
177. Krechler, T.; Zeman, M.; Vecka, M.; Macasek, J.; Jachymova, M.; Zima, T.; Zak, A. Leptin and adiponectin in pancreatic cancer: Connection with diabetes mellitus. Neoplasma 58:58-64; 2011.
178. Van Den Neste, E.; Van den Berghe, G.; Bontemps, F. AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. Expert Opin. Investig. Drugs 19:571-578; 2010.
179. Phoenix, K.; Vumbaca, F.; Claffey, K. P. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat. 113:101-111; 2009.
180. Loudon, J. A.; Billy, M. L.; DeYoung, B. R.; Allen, C. M. Angiosarcoma of the mandible: A case report and review of the literature. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 89:471-476; 2000.
181. Lahat, G.; Dhuka, A.; Hallevi, H.; Xiao, L.; Zou, C.; Smith, K.; Phung, T.; Pollock, R. E.; Benjamin, R.; Hunt, K. K.; Lazar, A. J.; Lev, D. Angiosarcoma: Clinical and molecular insights. Ann. Surg. 251:1098-1106; 2010.
182. Tokuyama, W.; Mikami, T.; Masuzawa, M.; Okayasu, I. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. Hum. Pathol. 41:407-414; 2010.
183. Sharma, S.; Dewald, O.; Adrogue, J.; Salazar, R. L.; Razeghi, P.; Crapo, J. D.; Bowler, R. P.; Entman, M. L.; Taegtmeyer, H. Induction of antioxidant gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species. Free Radic. Biol. Med. 40:2223-2231; 2006.
184. Lee, H. J.; Do, J. H.; Bae, S.; Yang, S.; Zhang, X.; Lee, A.; Choi, Y. J.; Park, D. C.; Ahn, W. S. Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma. Med. Oncol.; in press.
185. Saga, Y.; Ohwada, M.; Suzuki, M.; Konno, R.; Kigawa, J.; Ueno, S.; Mano, H. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol. Rep. 20:1299-1303; 2008.
186. Chacko, S. M.; Ahmed, S.; Selvendiran, K.; Kuppusamy, M. L.; Khan, M.; Kuppusamy, P. Hypoxic preconditioning induces the expression of pro-survival and pro-angiogenic markers in mesenchymal stem cells. Am. J. Physiol. Cell Physiol. 299:1562-1570; 2010.
187. Zhuo, Y.; Chen, P. F.; Zhang, A. Z.; Zhong, H.; Chen, C. Q.; Zhu, Y. Z. Cardioprotective effect of hydrogen sulfide in ischemic reperfusion experimental rats and its influence on expression of survivin gene. Biol. Pharm. Bull. 32:1406-1410; 2009.
188. Thirunavukkarasu, M.; Han, Z.; Zhan, L.; Penumathsa, S. V.; Menon, V. P.; Maulik, N. Adeno-sh-beta-catenin abolishes ischemic preconditioning-mediated cardioprotection by downregulation of its target genes VEGF, Bcl- 2, and survivin in ischemic rat myocardium. Antioxid. Redox Signal 10:1475-1484; 2008.
189. Wohlschlaeger, J.; Meier, B.; Schmitz, K. J.; Takeda, A.; Takeda, N.; Vahlhaus, C.; Levkau, B.; Stypmann, J.; Schmid, C.; Werner Schmid, K.; Baba, H. A. Cardiomyocyte survivin protein expression is associated with cell size and DNA content in the failing human heart and is reversibly regulated after ventricular unloading. J. Heart Lung Transplant. 29:1286-1292; 2010.
190. Biran, A.; Brownstein, M.; Haklai, R.; Kloog, Y. Down- regulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy. Int. J. Cancer 128:691-701; 2011.
191. Pando, R.; Cheporko, Y.; Haklai, R.; Maysel-Auslender, S.; Keren, G.; George, J.; Porat, E.; Sagie, A.; Kloog, Y.; Hochhauser, E. Ras inhibition attenuates myocardial ischemia-reperfusion injury. Biochem. Pharmacol. 77: 1593-1601; 2009.
192. Zhang, L. X.; Zhao, Y.; Cheng, G.; Guo, T. L.; Chin, Y. E.; Liu, P. Y.; Zhao, T. C. Targeted deletion of NF- kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am. J. Physiol. Heart Circ. Physiol. 298:2154-2163; 2010.
193. Lee, H.; Ryu, S. H.; Hong, S. S.; Seo, D. D.; Min, H. J.; Jang, M. K.; Kwon, H. J.; Yu, E.; Chung, Y. H.; Kim, K. W. Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. J. Gastroenterol. Hepatol. 24:1445-1450; 2009.
194. Oceandy, D.; Cartwright, E. J.; Neyses, L. Ras-association domain family member 1A (RASSF1A) - where the heart and cancer meet. Trends Cardiovasc. Med. 19: 262-267; 2009.
195. Brookes, S.; Rowe, J.; Ruas, M.; Llanos, S.; Clark, P. A.; Lomax, M.; James, M. C.; Vatcheva, R.; Bates, S.; Vousden, K. H.; Parry, D.; Gruis, N.; Smit, N.; Bergman, W.; Peters, G. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J. 21: 2936-2945; 2002.
196. Kelland, L. R. Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opin. Investig. Drugs 12: 413-421; 2003.
197. Chatterjee, M.; van Golen, K. L. Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype. Int. J. Cancer 129:61-69; 2011.
198. Samuel, S.; Fan, F.; Dang, L. H.; Xia, L.; Gaur, P.; Ellis, L. M. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 30:1205-1212; 2011.
199. Lei, Y.; Geng, Z.; Guo-Jun, W.; He, W.; Jian-Lin, Y. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol. Cell. Biochem. 344:23-31; 2010.
200. Lekli, I.; Mukherjee, S.; Ray, D.; Gurusamy, N.; Kim, Y. H.; Tosaki, A.; Engelman, R. M.; Ho, Y. S.; Das, D. K. Functional recovery of diabetic mouse hearts by glutaredoxin-1 gene therapy: Role of Akt-FoxO-signaling network. Gene Ther. 17:478-485; 2010.
201. Sengupta, A.; Molkentin, J. D.; Yutzey, K. E. FoxO transcription factors promote autophagy in cardiomyocytes. J. Biol. Chem. 284:28319-28331; 2009.
202. Myatt, S. S.; Brosens, J. J.; Lam, E. W. Sense and sensitivity: FOXO and ROS in cancer development and treatment. Antioxid. Redox Signal. 14: 675-687; 2011.
203. Oh, W. K.; Cho, K. B.; Hien, T. T.; Kim, T. H.; Kim, H. S.; Dao, T. T.; Han, H. K.; Kwon, S. M.; Ahn, S. G.; Yoon, J. H.; Kim, T. H.; Kim, Y. G.; Kang, K. W. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxo- rubicin responsiveness via down-regulation of multidrug resistance 1. Mol. Pharmacol. 78:855-864; 2010.
204. Chen, L.; Feng, P.; Li, S.; Long, D.; Cheng, J.; Lu, Y.; Zhou, D. Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide. Neurochem. Res. 34:984-990; 2009.
205. Hien, T. T.; Kim, H. G.; Han, E. H.; Kang, K. W.; Jeong, H. G. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein ki- nase in breast cancer MCF-7/adr cells. Mol. Nutr. Food Res. 54:918-928; 2010.
206. Liu, F.; Liu, S.; He, S.; Xie, Z.; Zu, X.; Jiang, Y. Survivin transcription is associated with P-glycoprotein/ MDR1 overexpression in the multidrug resistance of MCF- 7 breast cancer cells. Oncol. Rep. 23:1469-1475; 2010.
207. Guo, X.; Ma, N.; Wang, J.; Song, J.; Bu, X.; Cheng, Y.; Sun, K.; Xiong, H.; Jiang, G.; Zhang, B.; Wu, M.; Wei, L. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8: 375-384; 2008.
208. Deschamps, A. M.; Murphy, E.; Sun, J. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc. Med. 20:73-78; 2010.
209. Wang, D.; Hu, L.; Zhang, G.; Zhang, L.; Chen, C. G protein-coupled receptor 30 in tumor development. Endocrine 38:29-37; 2010.
210. Deschamps, A. M.; Murphy, E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am. J. Physiol. Heart Circ. Physiol. 297: 1806-1813; 2009.
211. Zhong, B.; Wang, D. H. Protease-activated receptor 2- mediated protection of myocardial ischemia-reperfusion injury: Role of transient receptor potential vanilloid receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297:1681-1690; 2009.
212. Schaffner, F.; Versteeg, H. H.; Schillert, A.; Yokota, N.; Petersen, L. C.; Mueller, B. M.; Ruf, W. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood 116:6106-6113; 2010.
213. Hay, D. L.; Walker, C.; Poyner, D. Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: Opportunities and challenges. Endocr. Relat. Cancer 18:1-14; 2010.
214. Routhu, K. V.; Tsopanoglou, N. E.; Strande, J. L. Parstatin (1-26): The putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury. J. Pharmacol. Exp. Ther. 332:898-905; 2010.
215. Zania, P.; Gourni, D.; Aplin, A. C.; Nicosia, R. F.; Flordellis, C. S.; Maragoudakis, M. E.; Tsopanoglou, N. E. Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. J. Pharmacol. Exp. Ther. 328:378-389; 2009.
216. Agarwal, A.; Tressel, S. L.; Kaimal, R.; Balla, M.; Lam, F. H.; Covic, L.; Kuliopulos, A. Identification of a metalloprotease- chemokine signaling system in the ovarian cancer microenvironment: Implications for antiangiogenic therapy. Cancer Res. 70:5880-5890; 2010.
217. Liu, X.; Xu, F.; Fu, Y.; Liu, F.; Sun, S.; Wu, X. Calreticulin induces delayed cardioprotection through mitogen- activated protein kinases. Proteomics 6:3792-3800; 2006.
218. Lwin, Z. M.; Guo, C.; Salim, A.; Yip, G. W.; Chew, F. T.; Nan, J.; Thike, A. A.; Tan, P. H.; Bay, B. H. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod. Pathol. 23:1559-1566; 2010.
219. Wang, Y.; Chen, B.; Shen, D.; Xue, S. Osteopontin protects against cardiac ischemia-reperfusion injury through late preconditioning. Heart Vessels 24:116-123; 2009.
220. Zhang, Y.; Forootan, S. S.; Kamalian, L.; Bao, Z. Z.; Malki, M. I.; Foster, C. S.; Ke, Y. Suppressing tumouri-genicity of prostate cancer cells by inhibiting osteopontin expression. Int. J. Oncol. 38:1083-1091; 2011.
221. Srisakuldee, W.; Jeyaraman, M. M.; Nickel, B. E.; Tanguy, S.; Jiang, Z. S.; Kardami, E. Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovasc. Res. 83:672-681; 2009.
222. Sirnes, S.; Kjenseth, A.; Leithe, E.; Rivedal, E. Interplay between PKC and the MAP kinase pathway in Connexin43 phosphorylation and inhibition of gap junction intercellular communication. Biochem. Biophys. Res. Commun. 382:41-55; 2009.
223. Li, X.; Liao, Q. P. Expression of connexin 43 in ovarian cancer and its relationship with chemoresistance. Zhonghua Fu Chan Ke Za Zhi 44:50-55; 2009.
224. Korzick, D. H.; Kostyak, J. C.; Hunter, J. C.; Saupe, K. W. Local delivery of PKCepsilon-activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation. Am. J. Physiol. Heart Circ. Physiol. 293:2056-2063; 2007.
225. Mayr, M.; Liem, D.; Zhang, J.; Li, X.; Avliyakulov, N. K.; Yang, J. I.; Young, G.; Vondriska, T. M.; Ladroue, C.; Madhu, B.; Griffiths, J. R.; Gomes, A.; Xu, Q.; Ping, P. Proteomic and metabolomic analysis of cardioprotection: Interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. J. Mol. Cell Cardiol. 46:268-277; 2009.
226. Basu, A. PKCε paves the way for prostate cancer. Cell Cycle 10:378; 2011.
227. Bourguignon, L. Y.; Spevak, C. C.; Wong, G.; Xia, W.; Gilad, E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker nanog and the production of micro-RNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 284: 26533-26546; 2009.
228. Zhang, J.; Ping, P.; Wang, G. W.; Lu, M.; Pantaleon, D.; Tang, X. L.; Bolli, R.; Vondriska, T. M. Bmx, a member of the Tec family of nonreceptor tyrosine kinases, is a novel participant in pharmacological cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 287:2364-2366; 2004.
229. Guo, L.; Zhou, Y.; Sun, Y.; Zhang, F. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. Eur. J. Cancer 46:636-641; 2010.
230. Xu, T.; He, K.; Wang, L.; Goldkorn, A. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate 71:1390-1400; 2011.
231. Schneider, M. D. Dual roles of telomerase in cardiac protection and repair. Novartis Found Symp. 274:260-276; 2006.
232. Holmes, M. D.; Chen, W. Y.; Li, L.; Hertzmark, E.; Spiegelman, D.; Hankinson, S. E. Aspirin intake and survival after breast cancer. J. Clin. Oncol. 28:1467-1472; 2010.
233. Harris, R. E.; Beebe-Donk, J.; Doss, H.; Burr Doss, D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (review). Oncol. Rep. 13: 559-583; 2005.
234. Shinmura, K.; Tang, X. L.; Wang, Y.; Xuan, Y. T.; Liu, S. Q.; Takano, H.; Bhatnagar, A.; Bolli, R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl. Acad. Sci. USA 97:10197-10202; 2000.
235. Janakiram, N. B.; Rao, C. V. Role of lipoxins and resol- vins as anti-inflammatory and proresolving mediators in colon cancer. Curr. Mol. Med. 9:565-579; 2009.
236. Jenndahl, L. E.; Isakson, P.; Baeckström, D. c-erbB2-induced epithelial-mesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation. Int. J. Oncol. 27:439-448; 2005.
237. Fanjul, M.; Gmyr, V.; Sengenès, C.; Ratovo, G.; Dufresne, M.; Lefebvre, B.; Kerr-Conte, J.; Hollande, E. Evidence for epithelial-mesenchymal transition in adult human pancreatic exocrine cells. J. Histochem. Cytochem. 58: 807-823; 2010.
238. Borgers, M. Hibernating myocardium: Programmed cell survival or programmed cell death? Exp. Clin. Cardiol. 7:69-72; 2002.
239. da Silva, R.; Lucchinetti, E.; Pasch, T.; Schaub, M. C.; Zaugg, M. Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium. Physiol. Genomics 20:117-130; 2004.
240. Hao, J.; Song, X.; Song, B.; Liu, Y.; Wei, L.; Wang, X.; Yu, J. Effects of lentivirus-mediated HIF-1alpha knock- down on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther. 15:449-455; 2008.
241. Matsuzaki, S.; Szweda, P. A.; Szweda, L. I.; Humphries, K. M. Regulated production of free radicals by the mitochondrial electron transport chain: Cardiac ischemic preconditioning. Adv. Drug Deliv. Rev. 61:1324-1331; 2009.
242. Tertil, M.; Jozkowicz, A.; Dulak, J. Oxidative stress in tumor angiogenesis-therapeutic targets. Curr. Pharm. Des. 16:3877-3894; 2010.
243. Pagliaro, P.; Penna, C. Cardiac postconditioning. Antioxid. Redox Signal. 14:777-779; 2011.
244. Zhuo, C.; Wang, Y.; Wang, X.; Wang, Y.; Chen, Y. Cardioprotection by ischemic postconditioning is abolished in depressed rats: Role of Akt and signal transducer and activator of transcription-3. Mol. Cell. Biochem. 346:39-47; 2011.
245. Binker, M. G.; Binker-Cosen, A. A.; Richards, D.; Gaisano, H. Y.; de Cosen, R. H.; Cosen-Binker, L. I. Hypoxia-reoxygenation increase invasiveness of PANC-1 cells through Rac1/MMP-2. Biochem. Biophys. Res. Commun. 393:371-376; 2010.
246. Song, D. K.; Jang, Y.; Kim, J. H.; Chun, K. J.; Lee, D.; Xu, Z. Polyphenol (-)-epigallocatechin gallate during ischemia limits infarct size via mitochondrial K(ATP) channel activation in isolated rat hearts. J. Korean Med. Sci. 25:380-386; 2010.
247. de Souza, P. M.; Newson, J.; Gilroy, D. W. Targeting lipoxygenases with care. Chem. Biol. 13:1121-1122; 2006.
248. Srivastava, G.; Mehta, J. L. Currying the heart: Curcumin and cardioprotection. J. Cardiovasc. Pharmacol. Ther. 14:22-27; 2009.
249. Lekli, I.; Das, S.; Das, S.; Mukherjee, S.; Bak, I.; Juhasz, B.; Bagchi, D.; Trimurtulu, G.; Krishnaraju, A. V.; Sengupta, K.; Tosaki, A.; Das, D. K. Coenzyme Q9 provides cardioprotection after converting into coenzyme Q10. J. Agric. Food Chem. 56:5331-5337; 2008.
250. Hertz, N.; Lister, R. E. Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: A pilot study. J. Int. Med. Res. 37: 1961-1971; 2009.
251. Bahar, M.; Khaghani, S.; Pasalar, P.; Paknejad, M.; Khorramizadeh, M. R.; Mirmiranpour, H.; Nejad, S. G. Exogenous coenzyme Q10 modulates MMP-2 activity in MCF-7 cell line as a breast cancer cellular model. Nutr. J. 9:62-70; 2010.
252. Kavazis, A. N.; Alvarez, S.; Talbert, E.; Lee, Y.; Powers, S. K. Exercise training induces a cardioprotective phenotype and alterations in cardiac subsarcolemmal and intermyofibrillar mitochondrial proteins. Am. J. Physiol. Heart Circ. Physiol. 297:144-152; 2009.
253. Friedenreich, C. M. Physical activity and breast cancer: Review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res. 188:125-139; 2011.
254. Akhlaghi, M.; Bandy, B. Dietary broccoli sprouts protect against myocardial oxidative damage and cell death during ischemia-reperfusion. Plant Foods Hum. Nutr. 65: 193-199; 2010.
255. Qazi, A.; Pal, J.; Maitah, M.; Fulciniti, M.; Pelluru, D.; Nanjappa, P.; Lee, S.; Batchu, R. B.; Prasad, M.; Bryant, C. S.; Rajput, S.; Gryaznov, S.; Beer, D. G.; Weaver, D. W.; Munshi, N. C.; Goyal, R. K.; Shammas, M. A. Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: Potential use in chemoprevention and as adjuvant in chemotherapy. Transl. Oncol. 3:389-399; 2010.
256. Al-Abed, Y.; Mitsuhashi, T.; Li, H.; Lawson, J. A.; Fitz- Gerald, G. A.; Founds, H.; Donnelly, T.; Cerami, A.; Ulrich, P.; Bucala, R. Inhibition of advanced glycation endproduct formation by acetaldehyde: Role in the cardi- oprotective effect of ethanol. Proc. Natl. Acad. Sci. USA 96:2385-2390; 1999.
257. Kang, R.; Tang, D.; Loze, M. T.; Zeh, H. J. Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). Autophagy 7:91-93; 2011.
258. Wu, J. M.; Hsieh, T. C. Resveratrol: A cardioprotective substance. Ann. NY Acad. Sci. 1215:16-21; 2011.
259. Lee, S. J.; Kim, M. M. Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells. Life Sci. 88:465-472; 2011.
260. Qi, F.; Li, A.; Inagaki, Y.; Gao, J.; Li, J.; Kokudo, N.; Li, X. K.; Tang, W. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci. Trends 4:297-307; 2010.
261. Zhou, H.; Hou, S. Z.; Luo, P.; Zeng, B.; Wang, J. R.; Wong, Y. F.; Jiang, Z. H.; Liu, L. Ginseng protects rodent hearts from acute myocardial ischemia-reperfusion injury through GR/ER-activated RISK pathway in an endothelial NOS-dependent mechanism. J. Ethnopharmacol. 135:287-298; 2011.
262. Weber, D.; Wheat, J. M.; Curri, G. M. Inflammation and cancer: Tumor initiation, progression and metastasis, and Chinese botanical medicines. Zhong Xi Yi Jie He Xue Bao 8:1006-1013; 2010.
263. Yang, J.; Wang, J.; Zhu, S.; Chen, X.; Wu, H.; Yang, D.; Zhang, J. C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Mol. Cell. Biochem. 310:215-226; 2008.
264. Elsberger, B.; Lankston, L.; McMillan, D. C.; Underwood, M. A.; Edwards, J. Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis. 14:122-128; 2011.
265. Alloatti, G.; Arnoletti, E.; Bassino, E.; Penna, C.; Perrelli, M. G.; Ghé, C.; Muccioli, G. Obestatin affords cardio-protection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 299:470-481; 2010.
266. Nikolopoulos, D.; Theocharis, S.; Kouraklis, G. Ghrelin: A potential therapeutic target for cancer. Regul. Pept. 163:7-17; 2010.
267. Hong, R. A.; Iimura, T.; Sumida, K. N.; Eager, R. M. Cardio-oncology/ onco-cardiology. Clin. Cardiol. 33:733-737; 2010.
268. Asiri, Y. A. Probucol attenuates cyclophosphamide-induced oxidative apoptosis, p53 and Bax signal expression in rat cardiac tissues. Oxid. Med. Cell Longev. 3: 308-316; 2010.
269. Charitonidou, A. Epidaurus: The Sanctuary of Asclepius. In: Melas, E., ed. The Greek experience: A companion guide to the major architectural sites and an introduction to ancient history and myth. New York: E.P. Dutton & Co., Inc.; 1974:89-99.